PTGS2 and atherosclerosis: Analysis of network pharmacology and molecular docking confirmed that AKT1, caspase-3 (CASP3), MAPK1, MAPK3, NOS2, and prostaglandin-endoperoxide synthase 2 (PTGS2) were GZFL's potential target genes against atherosclerosis [84].